Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;9(5):453-457.
doi: 10.1016/j.tranon.2016.07.002.

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer

Domenico Ribatti  1 , Beatrice Nico  2 , Simona Ruggieri  2 , Roberto Tamma  2 , Giovanni Simone  3 , Anita Mangia  4
Affiliations
Review

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer

Domenico Ribatti et al. Transl Oncol. 2016 Oct.

Abstract

Several data support a central role for angiogenesis in breast cancer growth and metastasis. Observational studies have demonstrated that microvascular density (MVD) is a prognostic factor in invasive breast cancer, whereas others reached the opposite conclusion. Vascular endothelial growth factor is the most important angiogenic factor with proven significance in breast cancer, as it has been assessed in both experimental and clinical studies. Triple-negative breast cancer (TNBC) is a type of breast cancer which lacks estrogen, progesterone, and HER-2/neu receptors. MVD in both basal-like and TNBC is significantly higher than in non-basal-like and non-TNBC. In breast cancer and other malignancies, the development of agents that inhibit tumor angiogenesis has been an active area of investigation. In TNBC, clinical trials combining targeted agents and chemotherapy have failed to show substantial survival improvement. There is evidence that patients with TNBC may have a greater probability of obtaining some kind of clinical efficacy benefit from bevacizumab-based therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemical expression of VEGF-C (A), and VEGFR-3 (B) in bioptic samples of human breast cancer (courtesy of Prof. Anca Maria Cimpean).
Figure 2
Figure 2
Immunohistochemical expression of VEGF (A), HIF-1α (B), and CD31 (C) in bioptic samples of human breast cancer.
See this image and copyright information in PMC

References

    1. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL. Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124:966–978. - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implication. Proc Natl Acad Sci. 2001;98:10869–10874. - PMC - PubMed
    1. Arora R, Joshi K, Nijhawan R, Radotra BD, Sharma SC. Angiogenesis as an independent prognostic indicator in node-negative breast cancer. Anal Quant Cytol Histol. 2002;24:228–233. - PubMed
    1. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875–1887. - PubMed
    1. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8. - PubMed